Welcome to our dedicated page for CLXPF news (Ticker: CLXPF), a resource for investors and traders seeking the latest updates and insights on CLXPF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLXPF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLXPF's position in the market.
Cybin Inc. (OTCQB:CLXPF) reported substantial progress in its financial year ended March 31, 2021. Key highlights include phase II clinical trial approval for CYB001 targeting Major Depressive Disorder, expansion of its patent portfolio to 12 filings, and a cash balance of $64 million. The company raised $30 million through upsized financing, totaling approximately $90 million since 2019. CEO Doug Drysdale emphasized the company's commitment to advancing psychedelic therapeutics. However, the company posted a net loss of $32.2 million for the year, indicative of ongoing financial challenges.
Cybin, a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021, at 12:30 PM ET. The event will be available for live webcast at this link. Cybin utilizes proprietary drug discovery platforms and innovative delivery systems to develop treatments for psychiatric disorders. Caution is advised as forward-looking statements in the release may not reflect actual results due to inherent risks.
Cybin Inc. (OTCQB: CLXPF) has appointed Dr. Thomas Laughren to its Clinical Advisory Board. Dr. Laughren brings extensive experience from his 29 years at the FDA, where he oversaw psychiatric drug reviews. Along with other prominent additions, he is expected to provide critical insights into regulatory pathways for psychedelic treatments. The company aims to leverage this expertise to navigate potential challenges in psychiatric therapeutic development.
Cybin focuses on developing psychedelic therapeutics for mental health disorders using innovative drug delivery systems and proprietary discovery platforms.
Cybin Inc. (OTCQB:CLXPF) has announced the completion of its 51st pre-clinical study on its proprietary psychedelic molecules. The research includes over 50 novel compounds evaluated for safety and efficacy through collaborations with Contract Research Organizations. The Company has nominated one clinical candidate, CYB001, and three development candidates (CYB002, CYB003, CYB004) targeting Major Depressive Disorder, Alcohol Use Disorder, and Anxiety. Cybin aims to create commercially viable drugs with faster therapeutic onset times, enhancing convenience for both therapists and patients.
Cybin Inc. (OTCQB:CLXPF) will present at the Emerging Growth Conference on June 23, 2021, at 2:00 PM ET. Doug Drysdale, the CEO, will lead the presentation, which aims to highlight the company's advancements in psychedelic therapeutics for psychiatric disorders. The event will be available via a live webcast, and an archive will be posted on EmergingGrowth.com afterward. Cybin focuses on drug discovery and innovative delivery systems, seeking to address mental health challenges through science-backed developments.
Cybin Inc. (OTCQB:CLXPF) has chosen social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the primary targets for its psychedelic molecule CYB004. Anxiety affects millions globally, with SAD impacting 3-7% of U.S. adults and GAD affecting 3-6%. The U.S. market for SAD is estimated at $165M, while GAD's global market is projected to grow from $2.99B to $4.5B by 2027. Research indicates that psychedelic treatments can yield significant improvements in anxiety with fewer side effects compared to traditional medications, which often have slow onset times.
Cybin Inc. (OTCQB:CLXPF) announced that CEO Doug Drysdale will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. The presentation will be available on-demand starting at 7:00 AM ET and viewable for 90 days. Additionally, Drysdale will participate in a panel discussion titled 'Disruptive Psychopharmacology' at 9:00 AM ET. Cybin focuses on developing psychedelic therapeutics for psychiatric disorders through innovative drug discovery and delivery methods.
Cybin Inc. (OTCQB:CLXPF) announced a collaboration with the University of Washington to co-sponsor a randomized trial on the efficacy of psilocybin-assisted psychotherapy for healthcare professionals dealing with COVID-related distress. The trial aims to alleviate symptoms of depression, anxiety, and burnout among frontline workers. Led by Dr. Anthony Back, this initiative includes the EMBARK psychotherapy model, designed to support various clinical needs. Cybin emphasizes the importance of aiding distressed healthcare providers as they have faced significant challenges during the pandemic.
Cybin Inc. (OTCQB:CLXPF), a biotechnology firm focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present at the 2021 LD Micro Invitational XI. The event is scheduled for June 10, 2021, at 3:30 PM Eastern Time. Interested parties can view the presentation via a live webcast at this link. Cybin aims to address mental illness and addiction through innovative drug discovery and delivery methods. The company underscores the need for rigorous scientific research and clinical trials, noting that no medical claims have been validated.
Cybin Inc. (OTCQB:CLXPF) has announced sponsorship of a feasibility study utilizing Kernel's Flow technology to measure the psychedelic effects of Ketamine on cerebral cortex hemodynamics. This innovative device uses wearable neuroimaging technology to provide real-time measurement of brain activity. Cybin aims to enhance scientific understanding of psychedelic pharmacotherapy.
While the study marks a significant collaboration, statements include caution regarding the uncertainty surrounding future results and the need for rigorous clinical trials.
